



---

## ASX Announcement and Media Release

Wednesday 23 September 2015

SciGen Ltd

### **Supply & Distribution Agreement for Insulin in China – Harbin Gloria Pharmaceuticals Ltd.**

The Board of Directors of SciGen Limited (ASX:**SIE**) ("**SciGen**") announce that on 23 September 2015 SciGen signed an agreement for the supply and distribution of insulin within the territory of the People's Republic of China with Harbin Gloria Pharmaceuticals Co. Ltd ("**HGP**"), a company organised and existing under the laws of China. Another party to the agreement with HGP is Bioton SA ("**Bioton**"), a company organised and existing under the laws of Poland, (holding company of SciGen) and listed on the Warsaw Stock Exchange (WSE), which has the rights to produce the insulin commercialized by SciGen within the territory of the People's Republic of China. Under the agreement, HGP was granted exclusivity within the territory of the People's Republic of China and granted a licence for the "SciLin" trademark under which the insulin produced by Bioton is to be distributed.

Under the agreement for the supply and distribution of insulin HGP will be appointed as distributor and granted with license on the date immediately following the date of the termination of agreements between the Company, SciGen and Bayer Healthcare Company Limited, i.e., on 1 January 2016.

The insulin supply and distribution agreement was entered into for a term of ten (10) years.

#### **About SciGen**

SciGen Ltd is a progressive biopharmaceutical company involved in co-developing and marketing genetically engineered biopharmaceutical products for human healthcare. SciGen focuses in the areas of gastroenterology, endocrinology and immunology. Its product portfolio includes therapeutics such as rhuman Growth Hormone, rhuman Insulin and GCSF.

SciGen has acquired the rights to manufacture, distribute and market biopharmaceutical products under exclusive licensing arrangements. SciGen's portfolio currently includes proprietary biotechnology-derived products, and biosimilar products, which allows for faster entry into the market, as the biogeneric products have undergone much of the clinical development and trials required to bring new drugs to market. This minimises the risks associated with early stage product development.

SciGen currently undertakes R&D activities in collaboration with strategic partners and institutions.

SciGen's major strength lies in its ability to recognise the potential of new products in their early stages of development. Through joint collaboration with its strategic partners, SciGen uses its extensive expertise in regulatory and clinical environments, in conjunction with marketing and promotional infrastructure, to bring to market products which will have significant long-term benefit.

SciGen's business was established in 1988. SciGen is a Singapore biotechnology company, publicly listed on the Australian Stock Exchange (ASX code SIE). SciGen's headquarters is in Singapore and it also has subsidiary companies and offices in Australia, South Korea, China and Philippines, distribution channels in China, India, Malaysia, Myanmar, Pakistan, Thailand and Indonesia and a contract manufacturer in Poland, Bioton S.A.

<b>For further information: Company - Investor Relations</b>	<b>Company</b>
Ms. Gillian Dunlop SciGen (Australia) Pty Ltd +61 2 9485 1800 Email: <a href="mailto:gdunlop@scigen.com.au">gdunlop@scigen.com.au</a>	Slawomir Ziegert CEO SciGen Ltd +65 6779 6638